244 related articles for article (PubMed ID: 33712705)
1. BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
Ni M; Li J; Zhao H; Xu F; Cheng J; Yu M; Ke G; Wu X
Oncogene; 2021 Apr; 40(15):2711-2724. PubMed ID: 33712705
[TBL] [Abstract][Full Text] [Related]
2. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
3. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
4. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
6. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BRD4 triggers cellular senescence through suppressing aurora kinases in oesophageal cancer cells.
Xu JL; Yuan YJ; Lv J; Qi D; Wu MD; Lan J; Liu SN; Yang Y; Zhai J; Jiang HM
J Cell Mol Med; 2020 Nov; 24(22):13036-13045. PubMed ID: 32954665
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
Zheng J; Zhang Y; Cai S; Dong L; Hu X; Chen MB; Zhu YH
Cancer Lett; 2020 Apr; 476():129-139. PubMed ID: 32081805
[TBL] [Abstract][Full Text] [Related]
10. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
12. RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer.
Pranatharthi A; Thomas P; Udayashankar AH; Bhavani C; Suresh SB; Krishna S; Thatte J; Srikantia N; Ross CR; Srivastava S
J Exp Clin Cancer Res; 2019 Sep; 38(1):392. PubMed ID: 31488179
[TBL] [Abstract][Full Text] [Related]
13. SETD3 reduces KLC4 expression to improve the sensitization of cervical cancer cell to radiotherapy.
Li Q; Zhang Y; Jiang Q
Biochem Biophys Res Commun; 2019 Aug; 516(3):619-625. PubMed ID: 31235251
[TBL] [Abstract][Full Text] [Related]
14. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
16. Targeting HMGB3/hTERT axis for radioresistance in cervical cancer.
Li Z; Zhang Y; Sui S; Hua Y; Zhao A; Tian X; Wang R; Guo W; Yu W; Zou K; Deng W; He L; Zou L
J Exp Clin Cancer Res; 2020 Nov; 39(1):243. PubMed ID: 33187536
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma.
Wu Y; Wang Y; Diao P; Zhang W; Li J; Ge H; Song Y; Li Z; Wang D; Liu L; Jiang H; Cheng J
Theranostics; 2019; 9(6):1777-1793. PubMed ID: 31037138
[TBL] [Abstract][Full Text] [Related]
18. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
19. SOX9 is controlled by the BRD4 inhibitor JQ1 via multiple regulation mechanisms.
Hong SH; You JS
Biochem Biophys Res Commun; 2019 Apr; 511(4):746-752. PubMed ID: 30833074
[TBL] [Abstract][Full Text] [Related]
20. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC.
Shi L; Xiong Y; Hu X; Wang Z; Xie C
Int J Med Sci; 2021; 18(14):3090-3096. PubMed ID: 34400879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
